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Objectives This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory
markers in patients with chronic heart failure (CHF).
Background Endothelial dysfunction is commonly observed in patients with CHF, and it contributes to the limitation in exer-
cise capacity that accompanies this condition. Bacterial lipopolysaccharide may trigger proinflammatory cyto-
kine release and promote further endothelial dysfunction. UDCA, a bile acid used in the treatment of cholestatic
liver disease, has anti-inflammatory and cytoprotective properties and may contribute to the formation of
mixed micelles around lipopolysaccharide. These properties may help to improve peripheral blood flow in
patients with CHF.
Methods We performed a prospective, single-center, double-blind, randomized, placebo-controlled crossover study of
UDCA in 17 clinically stable male patients with CHF (New York Heart Association functional class II/III, left ven-
tricular ejection fraction 45%). Patients received in random order 500 mg UDCA twice daily for 4 weeks and
placebo for another 4 weeks. The primary endpoint was post-ischemic peak peripheral arm blood flow as as-
sessed by strain-gauge plethysmography.
Results Sixteen patients completed the study. UDCA was well tolerated in all patients. Compared with placebo, UDCA
improved peak post-ischemic blood flow in the arm (18%, p  0.038), and a trend for improved peak post-
ischemic blood flow in the leg was found (17%, p  0.079). Liver function improved: compared with placebo,
levels of -glutamyl transferase, aspartate transaminase, and soluble tumor necrosis factor  receptor 1 were
lower after treatment with UDCA than after placebo (all p  0.05). There was no change in 6-min walk test or
New York Heart Association functional class, and levels of tumor necrosis factor  and interleukin-6 were un-
changed or increased compared with placebo.
Conclusions UDCA is well tolerated in patients with CHF. UDCA improves peripheral blood flow and is associated with im-
proved markers of liver function. (Ursodeoxycholic Acid in Chronic Heart Failure; NCT00285597) (J Am Coll
Cardiol 2012;59:585–92) © 2012 by the American College of Cardiology Foundation
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failure is not merely restricted
to pump failure; marked ab-
normalities of the musculoskel-
etal, renal, neuroendocrine, and
immune systems are seen (1).
Endothelial dysfunction is a key
aspect of chronic heart failure
(CHF) that contributes to the
patient’s clinical symptoms (2)
and may thus have direct effects
on quality of life. Proinflamma-
tory cytokines are involved in en-
dothelial dysfunction (1), disease
progression, and the development
of muscle wasting (3,4). Tumor
necrosis factor (TNF)- appears
to be the most important cytokine in
this context. However, therapeutic
approaches to block the overproduction of TNF- using specific
ntibodies have largely failed (5–7).
See page 593
One hypothesis holds that proinflammatory cytokine
activation is a consequence of altered gut wall morphology
and barrier function (8,9). Thus, endotoxin, otherwise
known as lipopolysaccharide (LPS), a cell-wall component
from gram-negative bacteria, may enter the circulation
either through the edematous gut wall during periods of
heart failure decompensation or simply as a consequence of
an altered intestinal morphology (1). The inhibition of LPS
might be clinically more meaningful than targeting single
downstream cytokines (9,10). Ursodeoxycholic acid
(UDCA), a bile acid used in patients with cholestatic liver
diseases, is an interesting candidate in this respect because it
appears to be able to form mixed micelles around LPS
leading to its detoxification (11,12). UDCA is a physiologic
constituent of human bile that has been used in cholestatic
liver disease such as primary biliary cirrhosis (13). The drug
has been on the market in Japan since the 1950s and in
Western countries since the mid-1980s (14). Its structure
was first elucidated in 1936 by Iwasaki (15). In the 1970s, it
became clear that UDCA is able to dissolve gallstones (16).
We hypothesized that short-term administration of
UDCA to patients with CHF would yield improvements in
peripheral blood flow as a consequence of decreases in
proinflammatory cytokines. We performed a randomized,
Foundation; and has unrestricted research grants by Falk and Intercept. Dr. Coats is
a consultant to and a stockholder for PsiOxus. All other authors have reported that
they have no relationships relevant to the contents of this paper to disclose. Dr.
Poole-Wilson is deceased.
Abbreviations
and Acronyms
AP  alkaline phosphatase
AST  aspartate
transaminase
CHF  chronic heart failure
GGT  -glutamyl
transferase
LPS  lipopolysaccharide
NYHA  New York Heart
Association
sTNFR  soluble tumor
necrosis factor  receptor
TNF  tumor necrosis
factor
UDCA  ursodeoxycholic
acidManuscript received February 16, 2011; revised manuscript received September 22,
2011, accepted October 17, 2011.placebo-controlled, double-blind, crossover trial of UDCA
in stable CHF patients.
Materials and Methods
Patient recruitment and endpoints. We prospectively
studied 17 clinically stable patients with CHF who were
recruited from the Royal Brompton Hospital specialist heart
failure clinic (London, United Kingdom) with a diagnosis of
CHF according to then current guidelines of the European
Society of Cardiology (17) and a left ventricular ejection
fraction 45%. The etiology of heart failure was coronary
artery disease or dilated cardiomyopathy. Subjects with
exertional angina, signs of peripheral or pulmonary edema,
clinical signs of infection, severe neuromuscular disease,
rheumatoid arthritis, significant renal dysfunction (serum
creatinine 250 mol/l), or cancer were excluded. We also
excluded patients younger than 18 years of age and those
with a history of unstable angina, myocardial infarction, or
stroke within 3 months before the study.
The study was of a crossover design, randomized,
placebo-controlled and double-blind. None of the investi-
gators involved in clinical and laboratory assessments were
aware of the patients’ treatment allocation at any time
during the study. The study design is depicted in Figure 1.
After baseline assessment, patients were randomly assigned
to either therapy with UDCA (500 mg twice daily) or
matching placebo for 4 weeks. This treatment period was
followed by a washout period of another 4 weeks during
which the patients did not receive any study medication.
Finally, patients underwent another 4 weeks of treatment
during which each patient received the opposite treatment.
Assessments of all parameters were performed at baseline
and after each of the 2 treatment periods (UDCA and
placebo). UDCA capsules and matching placebo were
donated as an unrestricted grant from the manufacturer (Dr.
Falk Pharma GmbH, Freiburg, Germany). The manufac-
Figure 1 Study Design
Patients were assigned to 1 of 2 treatment arms and started on either ursode-
oxycholic acid (UDCA) or placebo. After a 4-week wash-out period, they
switched over to the other treatment.
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and was not involved in the analysis of the data.
The primary endpoint of the study was post-ischemic
peak arm blood flow after UDCA treatment versus placebo.
Secondary endpoints included changes in post-ischemic
peak leg blood flow, New York Heart Association (NYHA)
functional class and 6-min walk test as well as cellular
markers of immune function, serum levels of proinflamma-
tory cytokines, and LPS-stimulated cytokine production.
Previous randomized trials had shown that a dose of 10 to
15 mg/kg/day (mean dose 1,018 mg/day) is safe and
effective in reducing rejection rates in patients undergoing
liver transplantation (18–20). The dose used in our study
reflects this earlier experience. The local ethics committee
approved the study, and all subjects gave written informed
consent.
Blood collection and cytokine assessments. Citrated ve-
nous blood was collected early in the morning from an
antecubital vein after the patient rested in the supine
position for 15 min and processed within 1 h. After blood
collection, serum samples were immediately centrifuged and
stored at 80°C until final analysis. Serum levels of
nterleukin-6, TNF-, and soluble tumor necrosis factor-
receptor 1 (sTNFR-1) were determined using commercially
available high-sensitivity enzyme-linked immunosorbent
assay kits (Quantikine HS, R&D Systems, Minneapolis,
Minnesota). The lower limits of detection are 0.039 pg/ml,
0.106 pg/ml, and 7.8 pg/ml, respectively.
Whole blood 1-ml aliquots diluted 1:1 with RPMI 1640
supplemented with 10 U/ml heparin were placed in 1.5-ml
Eppendorf tubes. Escherichia coli–derived endotoxin (sero-
type 0111:B4) was added to achieve final concentrations of
0.1, 1, 10, and 100 ng/ml. Dilutions, aliquoting, and
stimulations were performed under sterile conditions. A
nonstimulated sample served as control. Whole blood sam-
ples were incubated for 6 h in a humidified atmosphere
(37°C, 5% CO2). After incubation, the samples were cen-
rifuged at 1,500 rpm for 5 min. The supernatants were
arvested and stored at 80°C until final assessment. Cell
iability was 90% as assessed using trypan blue exclusion.
oncentrations of TNF- in cell culture supernatant were
easured by standard enzyme-linked immunosorbent assay
its (R&D Systems) according to the manufacturer’s in-
tructions. The lower limits of detection were 15 pg/ml. All
amples were frozen at 80°C until analysis. All samples
ere analyzed in duplicate and thawed only once for
mmediate analysis.
ssessment of bile acids from serum. All bile acids (cholic
cid, deoxycholic acid, chenodeoxycholic acid, lithocholic
cid, UDCA) were assessed as unconjugated acids and as
aurine and glycine conjugates using a tandem mass spec-
rometry method as described previously (21). All subfrac-
ions of the bile acids (free acids and their corresponding
onjugates) were analyzed by 3 different multiple-reaction
onitoring experiments within 1 high-performance liquidhromatography run. High-performance liquid chromatog-aphy was performed on a reversed-phase (C18) column
hat used a methanol/water gradient for chromatographic
olution of isobaric bile acids. Quantitation was done by the
se of deuterated internal standards and correlation of peak
rea ratios in linear regression.
lood flow assessment. We used strain-gauge venous
cclusion plethysmography (EC4, D.E. Hokanson, Inc.,
ellevue, Washington) to assess arm and leg blood flow
provided in ml 100 ml1min1), as described previously
(22). This technique involves tying a strain gauge, a thin,
stretchable, mercury-filled elastic tube, around the entire
circumference of the limb. Because all patients enrolled in
the study were right-handed, all measurements were per-
formed at the largest part of the patient’s right arm or right
leg, respectively. Resting blood flow was assessed after 15
min of rest in the supine position with the right leg
comfortably rested and slightly elevated. Stimulated peak
blood flow during reactive hyperemia was assessed imme-
diately after relief from 3 min of total ischemia, which was
induced by external compression of the respective limb
using an inflatable cuff 30 mm Hg above systolic blood
pressure. Thereafter, blood flow was measured in 10-s
intervals for 2 min. The flow rate was recorded with a
plethysmograph. The highest flow results were considered
to be the peak blood flow.
Statistical analysis. Data are presented as mean  SD.
The primary (post-ischemic peak arm blood flow) and
secondary endpoints were analyzed for the presence of a
period or carryover effect as recommended by Hills and
Armitage (23). No such effect was found (with the excep-
tion of a period effect for alkaline phosphatase [AP]), and
the results are therefore presented together in this order:
baseline, treatment, and placebo. Simple regression, Student
unpaired and paired t tests, and the chi-square test were
used as appropriate. Repeated-measures analysis of variance
was used to analyze the effects of increasing doses of LPS ex
vivo. A p value 0.05 was considered significant.
Results
We enrolled 17 male patients with CHF of NYHA func-
tional classes II and III. Patient baseline demographic data
are provided in Table 1 and patient medications in Table 2.
Eight patients were allocated to the UDCA first and 9
patients to the placebo first treatment arm. Compliance was
100%, as assessed by counting the returned UDCA cap-
sules. UDCA was well tolerated in all study subjects, and
there were no significant differences between subjects in the
2 treatment groups with the exception of a slightly higher
aspartate transaminase (AST) level in the group that re-
ceived UDCA first (Table 1). During the first days of
participation, 1 subject withdrew consent. Unblinding re-
vealed that the patient was on placebo, and the patient was
withdrawn from all further analyses.
Blood flow assessment and clinical variables. After
UDCA treatment, no significant difference was detected in
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Compared with the placebo phase, UDCA improved peak
blood flow significantly: UDCA treatment increased post-
ischemic blood flow by 18% in the arm (p  0.038), and
there was a trend toward an increase of 17% in the leg (p 
0.079) (Fig. 2). This was not associated with an improvement in
NYHA functional class or 6-min walk test (Table 3).
Laboratory parameters, bile acids, and cytokines. Com-
pared with placebo, treatment with UDCA yielded a sig-
nificant increase in serum levels of tauro-UDCA and
glyco-UDCA (Table 3). There was a mean 16-fold increase
in UDCA, and a mean 67-fold increase in the serum levels
of all UDCA subfractions combined. Details on the other
bile acids are provided in the Online Table. No correlation
was detected between forearm blood flow and total or any of
the subfractions of UDCA (all p  0.05). We found
significant reductions in -glutamyl transferase (GGT) and
AST serum levels with UDCA treatment when comparing
serum values assessed after UDCA and placebo (Table 3). There
Baseline Data for Patients With CHF in the 2 TrTable 1 Baseline Data for Patients With CH
UDCA
Male/female 8/
NYHA functional class 2.3
Etiology (ischemic/nonischemic) 5/
Ejection fraction, % 32.5
Age, yrs 62.0
Body mass index, kg/m2 29.5
Systolic blood pressure, mm Hg 107.5
Diastolic blood pressure, mm Hg 67.4
Heart rate, min1 66.1
6-min walk test, m 407.8
Pacemaker or ICD, yes/no 5/
Hemoglobin, g/dl 13.4
White blood cells, 109/l 7.6
Sodium, mmol/l 136.5
Potassium, mmol/l 4.3
-Glutamyl transferase, U/l 47.3
Aspartate transaminase, U/l 25.1
Creatinine, mol/l 134.1
Glomerular filtration rate, ml/min 79.3
Values are mean  SD or n/n. NS with p  0.20. *Fisher exact test.
CHF  chronic heart failure; ICD  implantable cardioverter-defibri
Baseline Medication of the Patients With CHF iTable 2 Baseline Medication of the Patients
UDC
Loop diuretic, yes/no 7
ACE inhibitor, yes/no 5
Angiotensin receptor blocker, yes/no 4
Beta-blocker, yes/no 6
Spironolactone, yes/no 6
Digoxin, yes/no 5
Statin, yes/no 5
Aspirin, yes/no 4Values are n/n. NS with p  0.20.
ACE  angiotensin-converting enzyme; other abbreviations as in Table 1.was also a significant reduction in serum AP (Table 3). However,
there was a significant period effect of AP (p  0.02). No
changes in the serum concentrations of sodium, potassium,
creatinine, uric acid, total protein, albumin, C-reactive
protein, bilirubin, high-density lipoprotein, low-density li-
poprotein, and total cholesterol were noted (all p  0.15).
After UDCA treatment, we detected significant correlations
between total UDCAs and AST (r2  0.48, p  0.005) or
total bilirubin (r2  0.29, p  0.03). No such relationship
as detected between total UDCAs and AP, GGT, or
-reactive protein (all p  0.1). Furthermore, we detected a
ignificant decrease in serum levels of sTNFR-1 after UDCA
reatment compared with placebo (Table 3). No such changes
ere noted for interleukin-6 or TNF- (Table 3).
x vivo whole blood stimulation experiments. Whole
lood samples from patients with CHF released increasing
mounts of TNF- when stimulated with increasing doses of
LPS (data not shown). This was also true at baseline and after
the treatment period with either UDCA or placebo (repeated-
ent Groupshe 2 Treatment Groups
Placebo First p Value
8/0 NS*
2.6 0.4 NS
7/1 NS
30.4 10.1 NS
69.5 9.0 NS
28.7 6.6 NS
113.5 16.4 NS
69.4 10.3 NS
68.3 12.8 NS
3 391.3 85.1 NS
3/5 NS*
14.4 1.3 0.16
6.2 2.0 0.15
137.1 2.9 NS
4.5 0.5 NS
44.3 20.9 NS
18.8 3.5 0.0495
128.3 53.2 NS
69.0 30.9 NS
YHA  New York Heart Association; UDCA  ursodeoxycholic acid.
2 Treatment Groupsh CHF in the 2 Treatment Groups
t Placebo First p Value
7/1 NS
6/2 NS
5/3 NS
5/3 NS
6/2 NS
1/7 0.12
7/1 NS
5/3 NSeatmF in t
First
0
0.6
3
8.0
15.0
4.3
14.5
9.3
10.3
168.
3
1.3
1.6
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difference was noted between the amounts of TNF- released
fter any LPS dose when comparing assessments after UDCA
nd placebo treatment (all p  0.3).
Full blood count. Absolute numbers of leukocytes, neu-
trophils, and lymphocytes were significantly lower after
UDCA treatment than after placebo (Table 3). After
UDCA treatment, the number of neutrophils was lower
than after placebo (Table 3). Likewise, after UDCA treat-
ment, the number of lymphocytes was lower compared with
placebo (Table 3). No such difference was noted for mono-
cytes, eosinophils, or basophils (all p  0.15). No change
was detected for hemoglobin concentration between UDCA
treatment and placebo (Table 3). In addition, we detected
significant relationships between total UDCAs and the
absolute number of white blood cells (r2  0.34, p  0.02)
or the absolute number of lymphocytes (r2  0.29, p 
.03) after UDCA treatment.
iscussion
e show that 4 weeks of treatment with UDCA 500 mg
wice daily significantly increases post-ischemic blood flow
n the arm. In addition, there was a trend toward increased
ost-ischemic blood flow in the leg. These changes were
ssociated with significantly lower serum levels of sTNFR-1
nd significant reductions in the absolute numbers of neutro-
hils and lymphocytes after UDCA treatment compared with
lacebo. Additionally, we noted a reduction in GGT and AST
erum levels. However, these changes were not reflected in
mprovements in the 6-min walk test or NYHA functional
lass in our small study. No change was noted in LPS-
Figure 2 Resting and Post-ischemic Blood Flow
Assessment of resting (top panels) and post-ischemic (bottom panels) blood flow
plethysmography. UDCA  ursodeoxycholic acid.timulated TNF- secretion in peripheral blood ex vivo.DCA treatment at the dose used in this study is well
olerated in patients with CHF, in whom the drug has not
een used previously. Measurement of serum levels of bile acids
ay be useful to assess patient compliance.
For many years, reduced peripheral blood flow has been
ecognized to be one of the major factors limiting the
xercise capacity of patients with CHF (24). Although
ngiotensin-converting enzyme inhibitors and angiotensin
eceptor blockers are known to improve endothelial function
n cardiovascular illnesses and in heart failure, exercise
imitation remains a major issue, particularly in patients
ith CHF. Bile acids are known to have vasodilatory
roperties (25), and the finding that UDCA has beneficial
ffects on peripheral blood flow merits attention. The level
f improvement in peripheral blood flow observed in our
tudy is similar to that observed with diuretic therapy in
ecompensated heart failure (26) or with other drugs such as
llopurinol (27). Earlier studies had shown that liver func-
ion may have a role in patients with CHF because 2 studies
ound bilirubin to be a strong prognostic marker in patients
ith heart failure (28,29).
Deficiency in nitric oxide is associated with endothelial
ysfunction, and TNF- and other proinflammatory cyto-
kines have been associated with its development (2). Our
study was not designed to establish the underlying mecha-
nism; however, a direct induction of nitric oxide by UDCA
does not appear likely. This is in line with an earlier study
in 11 patients with coronary artery disease in whom 6 weeks
of treatment with UDCA yielded a significant improvement
in nitric oxide–independent endothelial vasodilation as as-
sessed by strain-gauge plethysmography in the forearm (30).
g both study periods in 16 patients. Blood flow was assessed using strain-gaugedurinThese investigators infused acetylcholine and nitroprusside
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vasodilation, respectively, and suggest that the anti-
inflammatory properties of UDCA might be responsible for
their findings (30). Indeed, an effect that interferes with
TNF- production or its (soluble) receptors appears possible.
We found significantly lower levels of sTNFR-1 after
UDCA treatment than after placebo. Although we cannot
exclude the possibility of a chance finding, sTNFR-1 is
indeed thought to better reflect long-term TNF- exposure
than TNF- itself (31). One of the properties of UDCA is
that it, like cholesterol, maintains membrane stability and
prevents membrane damage induced by mechanical and
chemical stress (32). Bile salts are present in bile as mixed
micelles that act as solubilizers and emulsifiers of choles-
terol, bilirubin, lecithin, fat-soluble vitamins, and also for
LPS (33). UDCA is present in human bile in small
amounts, forming about 3% of human bile (14). UDCA has
membrane-stabilizing and antiapoptotic effects (34). Apart
from effects on proinflammatory mediators, it is also possi-
ble that these indirect effects are involved in the improved
blood flow found in our study, although we could not detect
a direct relationship between serum levels of total UDCA or
its subfractions.
Indeed, Bährle et al. (35) reported that UDCA might
Changes in Functional Parameters and LaboratoTable 3 Changes in Functional Parameters
Ba
Functional parameters (secondary endpoints)
NYHA functional class 2.4
6-min walk test, m 400
Hemodynamics
Systolic blood pressure, mm Hg 110.5
Diastolic blood pressure, mm Hg 68.4
Heart rate, min1 67.2
Hemoglobin and white blood cells
Hemoglobin, g/dl 13.9
White blood cells, 109/l 6.9
Lymphocytes, 109/l 1.5
Monocytes, 109/l 0.39
Neutrophils, 109/l 4.7
Biochemistry, liver function, and bile acids
-Glutamyl transferase, U/l 45.8
Aspartate transaminase, U/l 21.9
Alkaline phosphatase, U/l 71.8
Bilirubin, mol/l 16.1
Total bile acids, mol/l 4.92
Total UDCA, mol/l 0.29
UDCA, mol/l 0.07
Tauro-UDCA, mol/l 0.02
Glyco-UDCA, mol/l 0.20
Serum cytokines
Interleukin-6, pg/ml 4.38
TNF-, pg/ml 3.05
Soluble TNF- receptor 1, pg/ml 2,390
Values are mean  SD. *UDCA treatment versus placebo; NS with p 
TNF-  tumor necrosis factor ; other abbreviations as in Table 1have beneficial effects after cardiac transplantation. In their Ustudy, they compared 21 cardiac allograft recipients receiv-
ing UDCA for cyclosporine-induced cholestasis (500 mg
twice daily, for 8 weeks) with 31 cardiac transplant
patients not receiving UDCA. They found that during the
first 6 months after transplantation, the number of acute
rejection episodes was significantly lower in the UDCA
group compared with the control group (p  0.005) (35).
This effect may be due to the immunomodulatory properties
of UDCA, which include suppression of the production of
cytokines like TNF- and interferon- but also modulation
f T-cell and B-cell function (36). This is in line with our
ndings because leukocyte counts decreased with UDCA
reatment compared with placebo. An elegant study was
resented by Aouad et al. (12), who showed that ligation of
he common bile duct in Lewis rats yielded significantly
levated levels of LPS in the bloodstream compared with
ontrol animals. This finding was highly suggestive that bile
cids are able to hold bacterial components back in the
ntestine. Indeed, application of chenodeoxycholic acid to
ats in this study was still associated with significantly
educed plasma LPS levels (12). Because elevated levels of
PS are present in patients with CHF (10), the improve-
ent in post-ischemic blood flow observed in our study may
e due to the formation of mixed micelles containing
rameters With UDCA Treatmentaboratory Parameters With UDCA Treatment
UDCA Placebo p Value*
2.4 0.5 2.4 0.5 NS
437 118 412 131 NS
3 109.8 21.3 109.9 20.3 NS
60.7 8.8 62.6 8.4 NS
3 67.4 12.8 68.2 12.1 NS
13.8 1.1 13.8 1.2 NS
6.9 1.6 7.6 1.7 0.0075
1.5 0.5 1.7 0.6 0.01
3 0.49 0.21 0.48 0.18 NS
4.6 1.5 5.1 1.5 0.025
1 29.3 12.2 37.2 21.3 0.009
19.0 5.9 22.3 5.6 0.02
7 76.9 35.2 69.2 28.2 0.01
15.3 5.8 14.7 3.1 NS
9 17.22 11.25 3.53 2.63 0.002
8 13.72 10.21 0.11 0.13 0.0006
0 7.16 5.18 0.02 0.04 0.0005
9 0.27 0.43 0.0 0.0 0.04
9 6.29 5.80 0.09 0.11 0.003
4 6.54 9.71 3.85 5.17 NS
0 2.91 1.19 2.61 1.17 NS
80 1,924 925 2,153 1,140 0.04ry Paand L
seline
 0.5
 129
 15.
 9.5
 11.
 1.4
 1.9
 0.5
 0.1
 1.6
 23.
 6.6
 27.
 4.3
 3.0
 0.5
 0.2
 0.0
 0.3
 3.1
 3.9
 1,2DCA around LPS. Consequently, fewer proinflammatory
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about an improvement in nitric oxide–independent endo-
thelial function. However, because not all measured proin-
flammatory mediators were affected, it is unlikely that this
pathway is the only one involved in the benefits seen with
UDCA treatment. Indeed, alternate mechanisms may have
an even stronger impact on the clinical effects of UDCA
seen in our study, and further testing of the role of LPS in
heart failure is warranted.
The fact that UDCA treatment in our study was associ-
ated with a significant reduction in serum AST and GGT
highlights the fact that an effective dose was used. However,
the dose of UDCA used in our study (1,000 mg/day) may
still have been too low to translate an improvement in
endothelial function into an improvement in clinical vari-
ables such as the 6-min walk test. The dose used in patients
with primary biliary cirrhosis, for example, is usually 10 to
16 mg/kg of body weight per day (i.e., 700 to 1,600 mg/day)
(13). Another possibility is that the duration of treatment in
our study was too short to achieve clinical improvements
(e.g., enhanced skeletal muscle function).
Study limitations. The number of patients was small, and
multiple statistical comparisons were performed, increasing
the likelihood that these results may be due to chance.
Although the implementation of a crossover design poten-
tiates its statistical power, the addition of a second baseline
assessment before the initiation of the second treatment
period might have provided additional information, espe-
cially because some of our findings were the result of
changes in the placebo group compared to baseline mea-
sures, rather than changes in the UDCA group per se.
UDCA was administered for a comparatively short time,
and it is not clear whether a longer time frame may have
potentiated the effects of UDCA. Although UDCA was
well tolerated in our study, it is noteworthy that rare but
typical side effects of UDCA include constipation, nausea,
and indigestion. It remains a matter of speculation whether
we used the optimal dose in patients with CHF; however,
the fact that serum levels of GGT and AST were reduced by
UDCA treatment highlights the fact that pathophysiologi-
cally relevant doses were used.
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